Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Asia. Further perceptions and practices of physicians and subjects about diabetes management in Asia will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No treatment given | Other | No treatment is given |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean age of onset of either type 1 or type 2 diabetes mellitus | study visit | |
| Mean duration of treatment of type 2 diabetes mellitus. | study visit | |
| Percentage of patients on either insulin therapy or OAD (oral anti-diabetic drug) therapy. | study visit | |
| Mean duration of diabetes in type 1 and type 2 diabetes patients respectively. | study visit | |
| Mean FPG (fasting plasma glucose),PPG (post prandial glucose) and HbA1c of diabetic patients. | study visit | |
| Percentage of diabetic patients with HbA1c target below or equal to 7.0%. | study visit | |
| Percentage of diabetic patients with HbA1c target below or equal to 6.5%. | study visit | |
| Percentage of diabetic patients having dyslipidemia and hypertension | study visit | |
| Percentage of diabetic patients having cardiovascular complications | study visit | |
| Percentage of diabetic patients having peripheral vascular disease | study visit | |
| Measure | Description | Time Frame |
|---|---|---|
| Patients' perception will be analysed through Patient questionnaire measuring:Psychological well-being, Quality of life and Patients' compliant to treatment | study visit | |
| Physician questionnaire measuring awareness about:HbA1c test and its goal, Anti-diabetic treatment and Barriers towards optimum diabetes control |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with diabetes mellitus (both type 1 and type 2) being treated at general hospitals, diabetes clinics and referral clinics will be selected according to inclusion and exclusion criteria. Patients will be selected randomly from clinic record/list to avoid any bias.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Jakarta | 12520 | Indonesia |
Not provided
| Label | URL |
|---|---|
| Clinical Trials at Novo Nordisk | View source |
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D003922 | Diabetes Mellitus, Type 1 |
| D003924 | Diabetes Mellitus, Type 2 |
| D048909 | Diabetes Complications |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood sample
| Percentage of diabetic patients having diabetic nephropathy |
| study visit |
| Percentage of diabetic patients having diabetic eye complications | study visit |
| study visit |
| Duration of diabetes associated with highest number of diabetic complications | study visit |
| Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, nephropathy and retinopathy) | study visit |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |